The Function of Tyrosine Hydroxylase in the Normal and Parkinsonian Brain

被引:24
作者
Tolleson, Christopher [1 ]
Claassen, Daniel [1 ]
机构
[1] Vanderbilt Univ, Dept Neurol, Nashville, TN 37232 USA
关键词
Gene therapy; oxidative stress; Parkinson's disease; tyrosine hydroxylase; ALPHA-SYNUCLEIN; GENE-THERAPY; N-TERMINUS; CATALYTIC-ACTIVITY; NONMOTOR SYMPTOMS; CRYSTAL-STRUCTURE; MESSENGER-RNA; DOPAMINE; DISEASE; PHOSPHORYLATION;
D O I
10.2174/187152712800792794
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Tyrosine hydroxylase (TH) is the rate limiting step in the biosynthesis of dopamine and other catecholamines. Differences have been noted in concentration and availability of this enzyme and its cofactors in disease states such as Parkinson's disease (PD) which are subject to alterations in catecholamines. More evidence suggests in fact that TH may play a direct role in the pathogenesis of PD, especially through oxidative stress and pro-inflammatory mechanisms. Treatment for PD has classically involved maximizing endogenous dopamine by medicinal options that either replace dopamine or augment the dopaminergic pathway. The medications are unfortunately limited, given they are not curative and involve potential short-term and long-term side effects. Gene therapy in PD is a burgeoning field which provides a way to augment dopamine production, and potentially protect the dopaminergic neurons from further degeneration. Given its importance in dopamine catabolism and the possibility that it may contribute to pathogenesis, TH is one target of gene therapy. Further research into the regulatory mechanisms and function of TH are promising in improving gene therapy approaches as well as other treatment modalities.
引用
收藏
页码:381 / 386
页数:6
相关论文
共 62 条
  • [1] ABATE C, 1991, J MOL NEUROSCI, V2, P203
  • [2] α-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity:: Lessons from viral transduction of knockout mice
    Alerte, Tshianda N. M.
    Akinfolarin, Akinwande A.
    Friedrich, Emily E.
    Mader, Samantha A.
    Hong, Chang-Sook
    Perez, Ruth G.
    [J]. NEUROSCIENCE LETTERS, 2008, 435 (01) : 24 - 29
  • [3] Epidemiology of Parkinson's disease
    Alves, Guido
    Forsaa, Elin Bjelland
    Pedersen, Kenn Freddy
    Gjerstad, Michaela Dreetz
    Larsen, Jan Petter
    [J]. JOURNAL OF NEUROLOGY, 2008, 255 (Suppl 5) : 18 - 32
  • [4] Gene Therapy for Dopamine Replacement in Parkinson's Disease
    Bjorklund, Anders
    Bjorklund, Tomas
    Kirik, Deniz
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2009, 1 (02)
  • [5] Bradbury MWB, 1997, J NEUROCHEM, V69, P443
  • [6] Ubiquitination of soluble and membrane-bound tyrosine hydroxylase and degradation of the soluble form
    Doskeland, AP
    Flatmark, T
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (05): : 1561 - 1569
  • [7] Functional effects of neuromelanin and synthetic melanin in model systems
    Double, K. L.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2006, 113 (06) : 751 - 756
  • [8] Influence of neuromelanin on oxidative pathways within the human substantia nigra
    Double, KL
    Ben-Shachar, D
    Youdim, MBH
    Zecca, L
    Riederer, P
    Gerlach, M
    [J]. NEUROTOXICOLOGY AND TERATOLOGY, 2002, 24 (05) : 621 - 628
  • [9] Iron dysregulation in movement disorders
    Dusek, Petr
    Jankovic, Joseph
    Le, Weidong
    [J]. NEUROBIOLOGY OF DISEASE, 2012, 46 (01) : 1 - 18
  • [10] Dopamine synthesis, uptake, metabolism, and receptors: Relevance to gene therapy of Parkinson's disease
    Elsworth, JD
    Roth, RH
    [J]. EXPERIMENTAL NEUROLOGY, 1997, 144 (01) : 4 - 9